D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX)

D. Boral Capital reaffirmed their buy rating on shares of Quince Therapeutics (NASDAQ:QNCX - Free Report) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $12.00 price target on the stock.

A number of other brokerages have also issued reports on QNCX. RODMAN&RENSHAW raised Quince Therapeutics to a "strong-buy" rating in a research report on Tuesday, October 29th. Brookline Capital Management started coverage on shares of Quince Therapeutics in a research report on Wednesday, December 18th. They set a "buy" rating and a $9.00 price target for the company. Maxim Group assumed coverage on shares of Quince Therapeutics in a report on Thursday, November 7th. They issued a "buy" rating and a $6.00 price target on the stock. EF Hutton Acquisition Co. I raised shares of Quince Therapeutics to a "strong-buy" rating in a report on Tuesday, October 22nd. Finally, Rodman & Renshaw started coverage on shares of Quince Therapeutics in a research note on Tuesday, October 29th. They issued a "buy" rating and a $11.00 target price on the stock. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $9.50.

Quince Therapeutics Stock Down 6.3 %

Quince Therapeutics stock traded down $0.10 during midday trading on Wednesday, hitting $1.48. 347,655 shares of the company were exchanged, compared to its average volume of 126,175. The company has a market cap of $65.12 million, a PE ratio of -1.19 and a beta of 0.61. The company's fifty day moving average price is $1.79 and its 200-day moving average price is $1.27. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $2.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Anfield Capital Management LLC acquired a new stake in Quince Therapeutics during the fourth quarter worth about $50,000. Scharf Investments LLC acquired a new stake in shares of Quince Therapeutics during the 4th quarter worth approximately $170,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Quince Therapeutics by 24.2% in the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company's stock worth $263,000 after purchasing an additional 66,170 shares during the last quarter. 30.75% of the stock is owned by institutional investors and hedge funds.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.